ELAREM™ Prime is the worldwide first affordable cell culture supplement based on human platelets offering the same benefits as FBS – in an animal serum-free environment. What is ELAREM™ Prime? It is derived from reused transfusion-approved platelets. These platelets can no longer be used for blood transfusions,
Introducing our new human Platelet Lysate brand name: ELAREM™ As a university spin-off, we started manufacturing our human Platelet Lysates (hPL) back in 2015, as ‘PL Solution’ products. For more than five years, you may know our human Platelet Lysates under this name. It is time
We look forward attending the virtual DxPx international partnering conference from 17-21st November 2020. Even if this year will be special due to Covid19, we are happy to connect with you on a virtual level. For the second time, the DxPx partnering conference is a parallel event
A new publication from Kouroupis et al. published in CYTOTHERAPY in July 2020 found out that infrapatellar fat pad (IFP)-mesenchymal stem cells (MSCs) manufactured with human Platelet Lysate (hPL) show enhanced immunomodulatory properties. Findings have potential for a minimally invasive cell therapy for joint disease The authors even
It is a pleasure for us to announce that BORN2GROW GmbH & Co. KG, a subsidiary of Zukunftsfonds Heilbronn (ZFHN), invests in our company and technology. Since almost 20 years the ZFHN successfully consults and accompanies start-up technologies and companies. BORN2GROW is the second investor in
Read in the press article from the "Aachener Zeitung" why human Platelet Lysate is still unusual but morally inoffensive PL BioScience produces human Platelet Lysate (hPL) as a cell culture supplement. This is still unusual because using the controversial Fetal Bovine Serum (FBS) for cell culture
PL BioScience will be at the virtual Cell Therapy Manufacturing & Gene Therapy Congress 2020 Also this year from October 19 to 22, 2020 we will participate the international congress for Cell & Gene Therapy The year 2020 is a special year and we are glad to
The TechVision Fonds brings in new capital in PL BioScience We are proud to announce that with the support of SilverSky LifeSciences we successfully managed to convince the TechVision Fonds to invest in our start-up business. The TechVision Fonds, managed by the S-UBG group, supports innovative start-up
The study performed with human Platelet Lysate (hPL) at the University of Miami showed an enhanced performance of manufactured IFP - MSCs under regulatory compliant conditions. The aim of the study was to proof the hypothesis: IFP-MSCs manufactured under these conditions do not need "ex-vivo priming
Meet PL BioScience at the annual GSCN Conference From 23 to 25 September the annual Conference of the German Stem Cell Network (GSCN) will take place. We will be part of it in the virtual exhibition. Special times require special actions Because of the corona safety requirements and
